Fiera Capital Corp Buys New Position in Repligen Corporation (RGEN)

Fiera Capital Corp bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 63,200 shares of the biotechnology company’s stock, valued at approximately $2,619,000. Fiera Capital Corp owned about 0.19% of Repligen Corporation at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the business. Teachers Advisors LLC grew its position in shares of Repligen Corporation by 11.4% during the fourth quarter. Teachers Advisors LLC now owns 56,695 shares of the biotechnology company’s stock worth $1,747,000 after acquiring an additional 5,819 shares during the last quarter. Bank of Montreal Can grew its position in shares of Repligen Corporation by 26.1% during the first quarter. Bank of Montreal Can now owns 37,036 shares of the biotechnology company’s stock worth $1,304,000 after acquiring an additional 7,675 shares during the last quarter. Great West Life Assurance Co. Can grew its position in shares of Repligen Corporation by 8.9% during the first quarter. Great West Life Assurance Co. Can now owns 48,403 shares of the biotechnology company’s stock worth $1,703,000 after acquiring an additional 3,964 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Repligen Corporation by 13.2% during the first quarter. BNP Paribas Arbitrage SA now owns 6,475 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 753 shares during the last quarter. Finally, Comerica Bank grew its position in shares of Repligen Corporation by 4.2% during the first quarter. Comerica Bank now owns 37,463 shares of the biotechnology company’s stock worth $1,382,000 after acquiring an additional 1,500 shares during the last quarter. Hedge funds and other institutional investors own 97.91% of the company’s stock.

Several research firms have recently commented on RGEN. BidaskClub upgraded shares of Repligen Corporation from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Janney Montgomery Scott upped their price target on shares of Repligen Corporation from $42.00 to $47.00 in a research report on Friday, June 23rd. Jefferies Group LLC restated a “hold” rating and set a $40.00 price target (up previously from $33.00) on shares of Repligen Corporation in a research report on Wednesday, June 28th. William Blair began coverage on shares of Repligen Corporation in a research report on Friday, July 21st. They set an “outperform” rating for the company. Finally, TheStreet upgraded shares of Repligen Corporation from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $42.00.

ILLEGAL ACTIVITY NOTICE: “Fiera Capital Corp Buys New Position in Repligen Corporation (RGEN)” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://sportsperspectives.com/2017/09/18/fiera-capital-corp-buys-new-position-in-repligen-corporation-rgen.html.

Repligen Corporation (NASDAQ:RGEN) opened at 44.32 on Monday. The company has a 50-day moving average of $42.01 and a 200-day moving average of $38.70. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81. The company has a market cap of $1.66 billion, a price-to-earnings ratio of 86.73 and a beta of 1.21.

Repligen Corporation (NASDAQ:RGEN) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The company had revenue of $32.40 million during the quarter, compared to analyst estimates of $31.72 million. During the same period last year, the company posted $0.16 earnings per share. The firm’s quarterly revenue was up 11.0% compared to the same quarter last year. Analysts predict that Repligen Corporation will post $0.59 EPS for the current year.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply